cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
ORALAIR® (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue...
Drawing on its in-depth knowledge of allergic diseases, and its unique expertise in allergy immunotherapy (AIT) for more than 50 years, Stallergenes thereby offers a comprehensive approach to improving the lives of allergy patients.
Patient expectations are at the core of Stallergenes innovation strategy. World leader in sublingual immunotherapy, Stallergenes provides efficient and patient-friendly allergy immunotherapy treatment options, such as shorter protocols to reduce the duration of treatment and the new convenient tablet form.
For more information, please visit Stallergenes' corporate website.